Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade

Ko, Chih-Chieh; Ho, Shinn‐Ying; Liu, Po Hong; Hsu, Chia-Yang; Hsia, Cheng Yuan; Huang, Yi‐Hsiang; Su, Chien–Wei; Lei, Hao‐Jan; Lee, Rheun‐Chuan; Hou, Ming‐Chih; Huo, Teh Ia

doi:10.1007/s10147-022-02117-9

Cited by 7 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More and more articles have proved that ALBI can be used not only in HCC but also in liver cirrhosis, hepatectomy, viral hepatitis, liver transplantation, acute liver failure, and a series of general measurements of liver function [36‒43]. ALBI can be modified or assembled as part of a new evaluation indicator.…”

Section: Discussionmentioning

confidence: 99%

Current Status and Future Direction of Albumin-Bilirubin in Hepatocellular Carcinoma: A Bibliometric Analysis

Zhang,

Yang,

Zhou

et al. 2023

Oncology

View full text Add to dashboard Cite

Introduction: Hepatocellular carcinoma (HCC) is a common malignant tumor, so we need a convenient and objective way to diagnose and treat HCC. We discuss the current situation, progress, hotspots and existing problems of albumin-bilirubin (ALBI) in HCC, which can provide new ideas for the prevention, diagnosis and treatment of HCC. Methods: We adopt Excel 2019 software and visual analysis tools based on Web of Science database search. This manuscript uses VOSviewer, Co-Occurrence13.3 (COOC13.3) software to conduct overall trend analysis, synonym merging, frequency of countries, journals, institutions, funds, dissimilarity matrices, co-occurrence matrices, bimodal matrices, coupling matrices, cluster analysis of topic evolution time zone graphs. Results: A total of 610 papers were included, and the number of papers output showed an overall upward trend. ALBI has been valued by the industry in HCC and plays an important role in diagnosing and treating HCC, even better than the classic Child-Pugh (C-P) grade. At the same time, hot spots in the treatment of HCC and other applications of ALBI were discovered. Conclusion: ALBI score is a convenient and objective liver function evaluation index, which plays an important role in the prediction of patient survival rate and prognosis. Promoting the ALBI score in HCC can help doctors judge the patient's condition and improve the diagnosis and precise treatment effect.

show abstract

Section: Discussionmentioning

confidence: 99%

Current Status and Future Direction of Albumin-Bilirubin in Hepatocellular Carcinoma: A Bibliometric Analysis

Zhang,

Yang,

Zhou

et al. 2023

Oncology

View full text Add to dashboard Cite

show abstract

“…Tumor markers (including α‐fetoprotein [AFP; HCC only], carcinoembryonic antigen [CEA], and carbohydrate antigen 19‐9 [CA19‐9; mCRC only]) were measured at baseline and at each follow‐up visit. In addition, Child–Pugh classification (for patients with HCC), ALBI score (for patients with HCC, calculated as previously reported), 8 and Eastern Cooperative Oncology Group performance status (ECOG PS) were assessed at baseline and at 6 months post‐SIRT.…”

Section: Methodsmentioning

confidence: 99%

Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium‐90 resin microspheres in Taiwan: data from the RESIN registry

Lee,

Liang,

Liang

et al. 2024

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and AimThe REgistry of Selective Internal radiation therapy in AsiaNs (RESIN) was a multicenter, single‐arm, prospective, observational study of 90Y resin microspheres in patients with hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC) from Taiwan. RESIN is the first real‐life clinical study of this therapy in an Asian cohort. Study objectives were to evaluate the safety and efficacy of 90Y resin microspheres.MethodsAdults with HCC or mCRC scheduled to receive SIRT with 90Y resin microspheres were included. Primary endpoints were best overall response rate (ORR), adverse events, and changes from baseline in liver function. Secondary efficacy endpoints included overall survival (OS).ResultsOf 107 enrolled patients, 83 had HCC, and 24 had mCRC. ORR was 55.41% (HCC) and 33.33% (mCRC). Of 58 HCC patients with 6‐month post‐SIRT data, 13.79% (n = 8) had resection, transplantation, transarterial chemoembolization, or radiofrequency ablation as the result of down‐staging or down‐sizing of their lesions. One hundred and ten treatment emergent adverse events (TEAEs) were reported in 51 patients, and five serious adverse events (SAEs) were reported in five patients. The most frequent TEAEs were abdominal pain, nausea and decreased appetite (HCC), and abdominal pain, decreased appetite, fatigue, and vomiting (mCRC). Two deaths due to SAEs (probably related to SIRT) were reported, both in patients with extensive HCC, active hepatitis infection, and other comorbidities. Median OS was 24.07 (HCC) and 12.66 (mCRC) months.ConclusionsSafety and efficacy outcomes with the routine use of SIRT with 90Y resin microspheres in Taiwan are consistent with published data.

show abstract

The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels

Wei

Chu

et al. 2023

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade

Cited by 7 publications

References 39 publications

Current Status and Future Direction of Albumin-Bilirubin in Hepatocellular Carcinoma: A Bibliometric Analysis

Current Status and Future Direction of Albumin-Bilirubin in Hepatocellular Carcinoma: A Bibliometric Analysis

Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium‐90 resin microspheres in Taiwan: data from the RESIN registry

The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels

Contact Info

Product

Resources

About